Building on SVI research from the BANDIT trial, Eli Lilly and Company has announced the launch of the BARICADE Phase 3 trials. This next stage of research will give people living with type 1 diabetes across 20 countries the opportunity to access this promising new therapy. Professor Thomas Kay led the groundbreaking BANDIT trial at SVI, in which baricitinib preserved pancreatic insulin production in people with newly-diagnosed type 1 diabetes. Professor John Wentworth, a pioneer of early screening for the disease, is now working to extend these discoveries to people at risk before symptoms appear. Find out more about the clinical trials: https://lnkd.in/gEQangyW
Medical discovery leading to real world transformative outcomes. Well done St Vincent's Institute of Medical Research, Thomas Kay and @John Wentworth
A huge milestone for the SVI and Eli Lilly teams — advancing from discovery to real-world impact for people with type 1 diabetes.
Company adviser & non-executive director
2wGroundbreaking research underpinning the possibility of a profound, positive impact on the lives of those with T1 Diabetes